## **REFERENCES**

- Arora, R.C., and Meltzer, H.Y. 1989. Increased 5-HT<sub>2</sub> receptor binding as measured by <sup>3</sup>H-lysergic acid diethylamide (<sup>3</sup>H-LSD) in the blood platelets of depressed. Life Sci. 44, 725-734.
- Azzaro, A.J and Ward, H.E. 1967. Drugs used in mood disorders. In: A.Burger,eds.

  Drugs affecting the central nervous system. pp. 397-411. New York: Mercel Dekker.
- Bannon, M.J., Granneman, J.G., and Kapatos, G. 1995. The dopamine transporter:

  Potential involvement in neuropsychiatric disorders. In: F.E. Bloom and

  D.J.Kupfer,eds. <u>Psychopharmacology: The fourth generation of Progress</u>. New

  York: Raven press.
- Barker, E.L. and Blakely, R.D. 1995. Norepinephrine and serotonin transporters: Molecular targets of antidepressant drugs. In: F.E. Bloom and D.J. Kupfer, eds.

  Psychopharmacology: The fourth generation of Progress. New York: Raven press.
- Baudrie, V., et al. 1993. Subchronic treatment with anxiolytic doses of the 5-HT1A receptor agonist ipsapirone does not affect 5-HT2 receptor sensitivity in the rat. <u>Eur J Pharmacol</u>. 261, 395-406.
- Borsini, F., Lecci, A., Mancinelli, A., de Aranno, V., and Meli, A. 1987. Stimulation of dopamine D<sub>2</sub> but not D<sub>1</sub> receptors reduces immobility time of rats in the forced swimming test: implication for antidepressant activity. <u>Eur J Pharmacol</u>. 148,301-307.
- Bourin, M. 1990. Is it possible to predict the activity of a new antidepressant in animals with simple psychopharmacological tests? <u>Fundam Clin Pharmacol</u>. 4, 49-64.
- Chanika Ratanachol. 1997. Effect of CU 763-14-01 and derivative on monoamine activities. Master's thesis, Department of Pharmacology, Graduate school, Chulalongkorn university.
- Charney, D.S., Menkes, D.B., Heninger, G.R. 1981. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. <u>Arch Gen Psychiatry</u>. 38, 1160-1180.

- Costall, B., Naylor, R.J., and Olley, J.E. 1972. The substantia nigra and stereotyped behaviour. <u>Eur J Pharmacol</u>. 18, 95-106.
- Cowen, P.J., et al. 1993. A role for 5-HT in the action of antidepressant drugs. <u>Pharmacol Ther</u>. 46, 43-51.
- Curet, O., Damoiseau, G., Aubin, N., Sontag, N., Rovei, V., and Jarreau, F.X. 1996.

  Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor I.

  Biochemical profile. <u>J Pharmacol Exp Ther</u>. 277(1), 253-64.
- Davis, R., Whittington, Ruth., and Bryson, H.M. 1997. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression.

  <u>Drug.</u> 53(4), 608-36.
- De Montis, G.M. 1990. Central dopaminergic transmission is selectively increased in the limbic system of rats chronically exposed to antidepressants. <u>Eur J Pharmacol</u>. 180, 31-35.
- Deutch, A.Y and Roth, R.H. 1999. Neurotransmitters. In: M.J. Zigmond, F.E Bloom, S.C Landis, J.L Roberts, and L.R. Squire, eds. <u>Fundamental neuroscience</u>. pp. 193-211. New York: Academic press.
- Dinan, T.G. 1996. Noradrenergic and serotonergic abnormalities in depression: Stress-induced dysfunction?. <u>J Clin Psychiatry</u>. 57(suppl 4), 14-18.
- Fields, E.D. 1982. Nomifensine maleate. <u>Drug Intell Clin Pharm</u>. 16(7-8), 547-52.
- Fulton, B. and Benfield, P. 1996. Moclobemide: an update of its pharmacological properties and therapeutic use. <u>Drug.</u> 52(3), 450-74.
- Ganong, W.F. 1997. <u>Review of medical physiology</u>, 18<sup>th</sup> ed. Connecticut: Lange medical publication.
- Garattni, S. 1997. Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: a review. <u>Int Clin Psychopharmacol</u>. 12 Suppl 3, S15-9.
- Geyer, M.A and Markou, A. 1995. Animal models of psychiatric disorders. In: Bloom, F.E.Bloom and D.J.Kupfer,eds. <u>Psychopharmacolohy: The fourth generation of progress</u>. New York: Raven press.
- Giral, P., Martin, P., Soubrie, P., and Simon, P. 1988. Reversal of helpless behaviour in rats by putative 5-HT1A agonist. <u>Biol Psychiatry</u>. 23, 237-242.

- Glick, S.D., et al. 1976. Screening and therapeutics: animal models and human problems.

  In: S.D.Click and J.Goldfarb,eds. <u>Behavioral Pharmacology</u>. pp. 340-348.

  Saint louis: The C.V Mosby company.
- Glowinski, J. and Iversen, L.L. 1966. The disposition of [3H] Norepinephrine, [3H] Dopamine and [3H] Dopa in various regions of the brain. <u>J Neurochem</u>. 13, 655-669.
- Goldfarb, J. and Wilk, S. 1976. Neuroanatomy, neurophysiology, and neurochemistry. In: S.D.Click and J.Goldfarb, eds. <u>Behavioral Pharmacology</u>. pp. 14-57. Saint louis: The C.V Mosby company.
- Goodwin, G.M. 1996. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs.

  J Clin Psychiatry. 57[suppl 4], 9-13.
- Hollinger, M., et al. 1969. Effect of reserpine, pargyline, alpha-methyl-p-tyrosine, and p-chlorophenylalamine on levorphanol-induced running activity in mice.

  <u>Arch Int Pharmacodyn.</u> 179,419-24.
- Horovitz, Z.P., et al. 1966. Effects of drugs on the mouse-killing (muricide) test and its relationship to amygdaloid function. <u>Int J Neuropharmacol</u>. 5, 405-411.
- Hoyer, D., et al. 1994. International union of pharmacology classification of receptors for 5- hydroxytryptamine (serotonin). <u>Pharmacol Reviews</u>. 46(2), 157-93.
- Kan, J.P., Mouget-Goniot, C., Worms, P., and Biziere, K. 1986. Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat.

  <u>Biochem Pharmacol</u>. 35(6), 973-978.
- Katz, R.J., et al. 1982. Animal model of depression: pharmacological sensitivity of a hedonic defecit. <u>Pharmacology. Biochemistry & Behaviour</u>. 16, 965-68.
- Khanna, J.M. 1967. Drugs used in mood disorders. In: A.Burger,eds. <u>Drugs affecting the central nervous system</u>. pp 281-88. New York: Mercel Dekker.
- Kilts, C.D. 1994. Recent pharmacologic advances in antidepressant therapy. <u>Am J Med</u>. 97(suppl 6A), 35-125.
- Kinney, J.L. 1985. Nomifensin maleate: a new second-generation antidepressant.

  Clin Pharm. 4(6), 625-36.

- Krstulovic, A.M and Powell, A.M. 1979. Use of native fluorescence measurement and stopped-flow scanning technique in the high-performance liquid chromatographic analysis of catecholamines and related compounds.

  <u>Journal of Chromatography</u>. 171, 345-356.
- Lehmann, H.E. 1959. Psychiatric concepts of depression: Nomenclature and classification. <u>Canad Psychiat Assoc J.</u> 4, 1-12.
- Leonard, B.E. 1995. Mechanism of action of antidepressants. CNS Drugs.4(suppl.1), 1-12
- Lew, R., et al. 1991. Dopamine transporter: deglycosylation with exo-and endoglycosylases. Brain Res. 539,239-46.
- Lotufo-Neto, F., Trivedi, M., and Thase, M. 1999. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neurosychopharmacol. 20(3), 226-47.
- Majeroni, B.A., and Hess, A. 1998. The pharmacologic treatment of depression.

  Am Board Fam Pract. 11(2), 127-139.
- Mann, J.J., Stanley, M., McBride, P.A., and McEwen, B.S. 1986. Increased 5-HT2 and β-adrenergic receptor binding in the frontal cortices of suicide victims.

  <u>Arch Gen Psychiatry</u>. 43,945-59.
- Mannito, P.T., Lang, A., Rauhala, P., and Vasar, E. 1995. Beneficial effects of co-administration of catechol-o-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. <u>Eur J Pharmacol</u>. 274, 229-33.
- Matsuno, K., Kobayashi, T., Tanaka, M.K., and Mita, S. 1996. σ 1 receptor subtype is involved in the relief of behavioural despair in the mouse forced swimming test. Eur J Pharmacol. 312, 267-71.
- Mckinney, W.T and Bunney, W. E. 1969. Animal Model of Depression, Review of evidence: Implications for research. <u>Arch Gen Psychiat</u>. 21,240-48.
- Mitchell, P.B. 1995. Novel french antidepressants not advailable in the United States.

  Psychopharmacology Bull. 31(3), 509-19.
- Napawan Wongsomnuk. 1998. Effect of CU 763-14-10 on isolated rat liver mitochondial monoamine oxidase activities. Master's thesis, Department of Pharmacology, Graduate school, Chulalongkorn university.

- Neal, M.J. 1994. Drugs used in affective disorders –antidepressants. In: Medical Pharmacology at a Glance. pp.60-61. MA: Blackwell Scientific Publication.
- Neff, N.H., and Yang, H.-Y. 1974. Minireview :Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs. <u>Life Sci.</u> 14,2061-2074.
- Okada, F., Tokumitsu, Y., and Ui, M. 1986. Desensitization of β-adrenergic receptor-coupled adenylate cyclase in cerebral cortex *in vivo* treatment of rats with desipramine. J Neurochem. 47, 454-59.
- Philip, B., et al. 1995. Novel French Antidepressants Not Available in the United States.

  Psychopharmacol Bull. 31(3), 509-19.
- Pratt, J.P. 1994. Affective disorder. In: R.Walker and C.Edwards,eds. <u>Clinical pharmacy</u> and therapeutics. pp. 389-402. New York: Churchill Livingstone.
- Perontka, S.J. 1993. 5-hydroxytryptamine receptor. <u>J Neurochem</u>. 60,408.
- Perontka, S.J. 1995. 5-hydroxytryptamine receptor subtype: Their evolution and clinical relevance. CNS Drugs. 4(suppl. 1), 18-28.
- Persolt, R.D., Bertin, A., Blavet, N., Deniel, M., and Jalfre, M. 1977. Behavioural despair in mice: a primary screening test for antidepressants. <u>Archs Int Pharmacody</u>

  <u>Therapie</u>. 229(2), 327-36.
- Persolt, R.D., et al. 1979. Immobility induced by forced swimming in rats: Effects of agents which modify central catecholamine and serotonin activity. <u>Eur J Pharmacol</u>. 57, 201-10.
- Poncelet, M., Chermat, R., and Simon, P. 1985. Psychopharmacological effects of nomifensine enantiomers. <u>Eur J Pharmacol</u>. 113, 271-74.
- Preskorn, S.H. 1999. What is depression. In: <u>Outpatient management of depression</u>:

  A guide for the primary-care practitioner, Second Edition. Professional communications. Inc.
- Quinton, R.M. 1963. The increase in the toxicity of yohimbine induced by imipramine and other drugs in mice. <u>Br J Pharmacol</u>. 21, 51-66.
- Reyes-Parada, M., et al. 1994. Monoamine oxidase inhibitory effects of some 4-aminophenethylamine derivatives. <u>Biochem Pharmacol</u>. 47(8), 1365-71.

- Redrobe, J.P., MacSweeney, C.P., and Bourin, M. 1996. The role of 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> receptors in antidepressant drug actions in the mouse forced swimming test.

  <u>Eur J Pharmacol</u>. 318, 213-20.
- Rubin, R., Malone, M.H., Waugh, M.H., and Burke, J.C. 1957. Bioassay of rauwolfia roots and alkaloids. <u>J Pharmaacol Exp. Ther</u>. 120, 125-36.
- Sanghvil, Gershon S. 1969. The evaluation of central nervous system stimulants in a new laboratory test for antidepressants. <u>Life Sci.</u> 8, 449-57.
- Schildkraut, J.J. 1965. The catecholamine hypothesis of affective disorder: A review of supporting evidence. Am J Psychiatry. 122, 509-22.
- Schloss, P and Williams, D.C. 1998. The serotonin transporter: a primary target for antidepressant drugs. <u>J Psychopharmacol</u>. 12(2),115-21.
- Seeman, P. 1995. Dopamine receptors. In: F.E.Bloom and D.J.Kupfer,eds.

  Psychopharmacology: The fourth generation of Progress. New York: Raven press.
- Sheldon, H.P. 1999. Evaluating the various antidepressants. In: <u>Outpatient management</u>
  of depression: A guide for the primary-care practitioner, Second Edition.

  Professional communications. Inc.
- Sigg, E.B. 1967. Animal techniques for evaluating antidepressants. In H.Brill,eds.

  Neuropsychopharmacology. pp. 331-33. Amsterdam: Excerpta Medica Foundation.
- Simiand, J., et al. 1992. Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical  $\beta$  adrenoceptors. <u>Eur J Pharmacol</u>. 219, 193-201.
- Smith, H.P., Nichols, D.E., Mailman, R.B., and Lawler, C.P. 1997. Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. <u>Eur J Pharmacol</u>. 323, 27-36.
- Sofia, R.D. 1969b. Structural relationship and potency of agents which selectively block mouse killing (muricide) behaviour in rats. <u>Life Sci.</u> 8,1201-10.
- Stahl, S. 1994. 5-HT1A receptor and pharmacotherapy: Is serotonin receptor down regulation linked to the mechanism of action of antidepressant drugs?

  Psychopharmacol Bull. 30(1), 39-43.

- Stanley, M. and Mann, J.J. 1983. Increased 5-HT2 binding sites in frontal cortex of sucide victims. Lancet. 1, 214-16.
- Sugrue, M.F. 1983. Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. <u>Pharmacol Ther.</u> 21, 1
- Sulser, F. 1984. Antidepressant treatments and regulation of norepinephrine-receptor-coupled adenylate cyclase in brain. <u>Adv Biochem Psychopharmacol</u>.39,249-61.
- Sutthatip Prayacharinkorn. 1997. Synthesis of cyclic acetal and ketal derivatives of pyridoxine. Master's thesis, Department of Pharmaceutical chemistry, Graduate school, Chulalongkorn university.
- Takeuchi, H., et al. 1997. Pharmacological studies on YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT2A receptor antagonistic activity. <u>Eur J Pharmacol</u>. 329, 27-35.
- Thiebot, M.H., Martin, P., and Puech, A.J. 1992. Animal behavioural studies in the evaluation of antidepressant drugs. <u>Brit J Psychiatry</u>. 160(suppl. 15), 44-50.
- Trullas, R., Folio, T., Young, A., Miller, R., Boje, K., Skolnick, P. 1991. I Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. <u>Eur J Pharmacol</u>. 203, 379-85.
- Von Moltke, L.L., et al. 1995. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. <u>Cli Pharmacokinet</u>. 29 suppl, 1:33-44.
- Willner, P. 1984. The validity of animal models of depression. <u>Psychopharmacology</u>. 83, 1-16.
- Willer, P. 1995. Dopaminergic mechanisms in depression and mania. In: F.E.Bloom and D.J.Kupfer,eds. <u>Psychopharmacology: The fourth generation of Progress</u>. New York: Raven press.
- Zifa, E and Fillion, G. 1992. 5-Hydroxytryptamine receptors. <u>Pharmacological reviews</u>. 44(3),401-40.

## CUMICULUM VITAE

Miss Phantip Watcharasinthu was born on April 23<sup>th</sup>, 1966, in Suratthani Province. She finished primary school education from Koh-Phangan (One of the islands in Suratthani) and secondary school education at Sam-Sen college, Phayathai. She graduated with Bachelor degree from Faculty of Pharmaceutical Sciences, Songklhanakarin University in 1990. After graduation, she worked as the pharmacist at Suratthani hospital. At the present she has worked at Prasat Neurological Institute, Bangkok.

